Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|September 25, 2024

Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

Author(s)Pearl Grimes, MD, FAAD

Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.

Episodes in this series

EP. 1 Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

EP. 1 Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

EP. 2 Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP. 2 Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP. 3 Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP. 3 Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP. 4 Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

EP. 4 Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

AI-Assisted Imaging Tracks Success of Low-Fluence QSRL Laser for Melasma